Alzheimer's Disease and Dementia
Our work in Alzheimer's Disease and Dementia
-
Benzodiazepines Don’t Increase Dementia Risks in Older Adults, USC Study Finds
There is little evidence that older adults prescribed benzodiazepines are at increased risk of developing dementia.
-
Access to Disease-Modifying Alzheimer’s Therapies: Addressing Possible Challenges Using Innovative Payment Models
Researchers use the Future Elderly Model to estimate potential benefits of disease-modifying therapies for Alzheimer disease.
-
Race and Ethnic Differences in the Association Between Alzheimer’s Disease Risk and Use of Prescription Medications for Chronic Conditions
Schaeffer Center experts analyze the connection between medications for chronic diseases and their impact on Alzheimer’s as well as a lack of representation among racial and ethnic minorities in clinical trials.
-
The Unequal Causes and Costs of Dementia
Dementia and its costs aren’t equally borne by all populations. Studies indicate that, compared to older non-Hispanic white adults, older Black adults are about twice as likely to have dementia, and older Hispanic adults about one and one-half times as likely.
Categorized in Evidence Base -
The Science of Alzheimer’s Disease and Related Dementias (ADRD) for Social Scientists Program
This two-day program aims to provide social science researchers with biomedical and clinical foundations of ADRD.
-
Interdisciplinary Hub Fosters Innovative Solutions for Improving Diversity in Clinical Trials
USC has received $5.8 million from Gates Ventures and the American Heart Association to launch a lab aimed at diversifying clinical trials.
-
Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers
Developing a blueprint to overcome challenges in implementing new payment models will ensure better access.
-
Approval and Reimbursement of Alzheimer’s Disease Therapies
On Monday, June 6, join the Schaeffer Center for a discussion about the regulatory challenges of approving and reimbursing therapies for Alzheimer’s disease.
-
Estimating the Value of Diagnosing and Treating Alzheimer’s Disease
On May 9, join a Schaeffer Center seminar to discuss improving access to new treatments, identifying the size of the treatment-eligible population, the need for affordable diagnostic tests, and how innovation could help pay for diagnostics and treatments to ensure the healthcare system has the capacity and resources to treat everyone in need.
-
Leveraging Alzheimer’s Disease Clinical Trial Outcomes in Health Economics Research
Join the Schaeffer Center for an academic seminar on the implications of clinical trial design on Alzheimer’s disease modeling.